Director at Replimune (REPL) awarded 44,500 stock options

Rhea-AI Filing Summary

Replimune Group, Inc. director Joseph P. Slattery received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. According to the disclosure, all 44,500 underlying shares vest in full on April 1, 2027. Following this grant, Slattery holds 44,500 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SLATTERY JOSEPH P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	44,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 44,500 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 44,500 options Exercise price: $7.61 per share Expiration date: April 1, 2036 +2 more

5 metrics

Stock options granted 44,500 options Grant to director Joseph P. Slattery on April 1, 2026

Exercise price $7.61 per share Strike price for 44,500 stock options

Expiration date April 1, 2036 Option term end for the granted awards

Vesting date April 1, 2027 All underlying shares vest entirely on this date

Holdings after grant 44,500 options Total stock options held directly following this transaction

Key Terms

Stock Option (right to buy), exercise price, vest entirely, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 7.6100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest entirely financial

"The shares underlying this option vest entirely on April 1, 2027."

expiration date financial

"expiration_date: 2036-04-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SLATTERY JOSEPH P

(Last) (First) (Middle)

C/O REPLIMUNE GROUP, INC.

500 UNICORN PARK DRIVE, SUITE 303

(Street)

WOBURN MASSACHUSETTS 01801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.61	04/01/2026		A		44,500		(1)	04/01/2036	Common Stock	44,500	$0	44,500	D

Explanation of Responses:

1. The shares underlying this option vest entirely on April 1, 2027.

Remarks:

This Form 4 is being filed late due to inadvertent administrative error.

	/s/ Shawn Glidden, attorney-in-fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Replimune (REPL) director Joseph P. Slattery report on this Form 4?

Joseph P. Slattery reported receiving a grant of stock options for 44,500 Replimune shares. These options are a compensation award, not an open-market purchase or sale, and give him the right to buy common stock at a fixed exercise price.

How many Replimune (REPL) shares are covered by Slattery’s new stock options?

The stock option grant covers 44,500 shares of Replimune common stock. Each option represents the right to purchase one share, giving Slattery potential future ownership if he chooses to exercise at or after vesting.

What is the exercise price of Joseph P. Slattery’s Replimune (REPL) stock options?

The options have an exercise price of $7.61 per share. This means Slattery can buy Replimune common stock at $7.61 per share once the options vest and before they expire, regardless of the market price at that time.

When do Joseph P. Slattery’s Replimune (REPL) options vest and become exercisable?

All shares underlying this option vest entirely on April 1, 2027. Vesting means the options become exercisable on that date, allowing Slattery to purchase Replimune common stock at the fixed exercise price if he chooses.

When do Joseph P. Slattery’s Replimune (REPL) stock options expire?

The stock options expire on April 1, 2036. After that expiration date, any unexercised options can no longer be used to buy Replimune shares, effectively becoming worthless if not exercised before the deadline.

Is this Replimune (REPL) Form 4 a market transaction or a compensation award?

This Form 4 reflects a compensation-related grant, not a market trade. The transaction code shows a grant or award acquisition of options, indicating the company granted Slattery options as part of his role rather than him buying shares on the open market.